What is AVIR (AVIR) stock price today?

AVIR (AVIR) is currently trading at $4.75, up 1.06% today.

What is AVIR P/E ratio?

AVIR's P/E ratio is -2.13. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AVIR return on equity (ROE)?

AVIR's return on equity (ROE) is -57.45%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is AVIR's market cap?

AVIR has a market capitalization of $380.13M.

NASDAQ · Biotechnology

AVIR (AVIR) Stock

$4.75 +1.06% NASDAQ: AVIR Healthcare

Valuation

Metric	Value
Price	$4.75
Market Cap	$380.13M
P/E Ratio	-2.13
P/B Ratio	1.21
P/S Ratio	0.00
EPS (TTM)	$-1.94
52-Week High	$6.45
52-Week Low	$2.78
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-57.45%
ROA	-50.16%
ROCE	-65.82%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	7.78

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$351.0M	$0	$0	$0	$0
Operating Profit	$138.0M	$-131.0M	$-164.0M	$-193.0M	$-181.0M
Net Profit	$121.0M	$-116.0M	$-136.0M	$-168.0M	$-158.0M
EPS	$1.37	$-1.39	$-1.63	$-2.00	$-1.94
Op Margin	39.4%	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$773.0M	$667.0M	$595.0M	$465.0M	$315.0M
Total Liabilities	$63.0M	$26.0M	$40.0M	$26.0M	$40.0M
Cash	$764.0M	$647.0M	$144.0M	$65.0M	$96.0M
Borrowings	$0	$3.0M	$2.0M	$2.0M	$1.0M

Latest News

Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment MT Newswires · Jul 14, 2026 Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus GlobeNewswire · Jul 14, 2026 Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America MT Newswires · Jun 25, 2026 Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus GlobeNewswire · Jun 25, 2026 Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know Zacks · Jun 18, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-87.0M	$-121.0M	$-85.0M	$-135.0M	$-132.0M
Investing Cash Flow	$0	$-457.0M	$40.0M	$56.0M	$189.0M
Financing Cash Flow	$0	$0	$0	$0	$-26.0M
Net Cash Flow	$-86.0M	$-576.0M	$-45.0M	$-79.0M	$31.0M
Free Cash Flow	$-87.0M	$-123.0M	$-85.0M	$-135.0M	$-132.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-43.89%
Quick Ratio	7.89
Interest Coverage	—
Return 1Y	36.10%
Return 3Y	33.80%
Return 5Y	-78.78%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHV	$6.66	+2.94%	-4.63	$683.71M	0.00%
ALLO	$1.95	+2.63%	-2.17	$673.05M	0.00%
ARCT	$6.26	+0.64%	-2.93	$177.93M	0.00%
ENTA	$12.61	-0.94%	-6.04	$366.68M	0.00%
HUMA	$0.66	-1.79%	-4.19	$110.81M	0.00%

About AVIR

AVIR is led by CEO Jean-Pierre Sommadossi, employs 56 people, headquartered in US, publicly traded since 2020.

AVIR stock trades at $4.75 with a market capitalization of $380.13M. The stock is valued at a price-to-earnings (P/E) ratio of -2.13, price-to-book of 1.21, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.78 and $6.45, and currently trades 26.4% below its 52-week high.

On profitability, AVIR generates a return on equity (ROE) of -57.45%, return on capital employed of -65.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides